[The effect of human recombinant erythropoietin on distribution of membrane phospholipids in blood platelets of patients with uremia treated with repeated hemodialysis].
An important role in the formation of hemostasis defects in uremic patients is attributed to platelet dysfunction. An essential role in platelet structure and function is played by membrane phospholipids (PL). They are asymmetrically distributed within the platelet membrane: outer surface is composed mainly of sphingomyelin (Sph) and phosphatidylcholine (PC). During platelet activation a translocation of phosphatidylserine (PS) and phosphatidylethanolamine (PE) from inner to outer membrane surface is observed. Phosphatidylinositol (PI) is not translocated. Lipid abnormalities are common in uremic patients. According to some authors erythropoietin (EPO) has been reported to alter lipid metabolism. In our recent works a positive influence of EPO on platelet PL composition in uremic patients has been indicated. The aim of this study was the assessment of the EPO influence (applied 4000 U per week) on platelet membrane PL distribution in chronically hemodialyzed patients. The PL distribution was determined using nonpenetrating tracer (TNBS) by Vale method, and using high purified phospholipases hydrolysis according to Chap method. Our results indicate that during EPO therapy the PS, PE, Sph and PC exposition at the outer surface of platelet membrane (in patients hemodialyzed without EPO widely disturbed compared with healthy controls) approaches to normal values. These results confirm our recent observations that EPO profoundly interferes with lipid metabolism. The smaller PS exposition at the outer platelet surface during EPO treatment suggests less platelet activation, and might partially explains the positive EPO influence on platelet hemostasis.
Krawczyk
W
W
Oddziału Chorób Wewnetrznych Szpitala Wojewódzkiego w Chełmie.
Ledwozyw
A
A
Dmoszyńska
A
A
Krzywicka
A
A
Rózyc
P
P
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D002462:Cell Membrane / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood*; D015539:Platelet Activation; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000628:therapy*
D010743:Phospholipids; D011994:Recombinant Proteins; D004921:Erythropoietin